Sue Bailey - EMERGENT BIOSOLUT Independent Director

ER4 Stock  EUR 5.33  0.15  2.90%   

Director

Dr. Sue Bailey, M.D., is an Independent Director of the Company. Dr. Bailey served as a news analyst for NBC Universal, a media and entertainment company, from November 2001 to August 2006. Previously, Dr. Bailey served as Administrator, National Highway Traffic Safety Administration, as Assistant Secretary of Defense and as Deputy Assistant Secretary of Defense . Dr. Bailey is a former faculty member at Georgetown Medical School and U.S. Navy officer, having achieved the rank of Lt. Commander, U.S. Navy Reserve since 2007.
Age 75
Tenure 18 years
Professional MarksPh.D
Bailey received her D.O. from Philadelphia College of Osteopathic Medicine and a B.S. from the University of Maryland. We believe Dr. Bailey qualifications to serve on our Board of Directors include her medical background and prior senior positions in government.

Similar Executives

Found 11 records

DIRECTOR Age

Christos IoannouAegean Airlines SA
47
NikolaosGeorgios NanopoulosAegean Airlines SA
N/A
Vittorio PisanteAegean Airlines SA
54
Bronwyn MorrisCollins Foods Limited
N/A
Georgios VasilakisAegean Airlines SA
47
Alexandros MakridisAegean Airlines SA
57
Steven BarneveldJAPAN AIRLINES
N/A
Konstantinos KalamatasAegean Airlines SA
N/A
Newman ManionCollins Foods Limited
64
Joel NichollsJAPAN AIRLINES
N/A
Panagiotis LaskaridisAegean Airlines SA
N/A
EMERGENT BIOSOLUT (ER4) is traded on Berlin Exchange in Germany and employs 18 people.

EMERGENT BIOSOLUT Leadership Team

Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer
Sean Kirk, Executive Vice President Manufacturing and Technical Operations
Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer
Fuad ElHibri, Executive Chairman of the Board
Sue Bailey, Independent Director
Jerome Hauer, Independent Director
Marvin White, Director
Kathryn Zoon, Independent Director
Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary
Seamus Mulligan, Director
George Joulwan, Independent Director
Adam Havey, Executive Vice President and Presidentident - BioDefense Division
Louis Sullivan, Independent Director
Ronald Richard, Lead Independent Director
Zsolt Harsanyi, Independent Director
Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer

EMERGENT Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in EMERGENT Stock

EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.